Table 2.

Recommended endpoints for NA treatment in HBeAg-negative CHB.

EASL 2017 [5]	AASLD 2018 [4]	APASL 2015 [7]
HBsAg loss	HBsAg loss	HBsAg loss
“Discontinuation of NAs in selected non-cirrhotic HBeAg-negative patients who have achieved long-term (3 years) virological suppression under NA(s) may be considered if close post-NA monitoring can be guaranteed”	-	“In patients without liver cirrhosis…treatment can be withdrawn after treatment for at least 2 years with undetectable HBV DNA documented on three separate occasions, 6 months apart”